Metformin-Associated Acute Kidney Injury and Lactic Acidosis by Arroyo, David et al.
SAGE-Hindawi Access to Research
International Journal of Nephrology
Volume 2011, Article ID 749653, 5 pages
doi:10.4061/2011/749653
Clinical Study
Metformin-AssociatedAcute KidneyInjuryandLactic Acidosis
DavidArroyo,Rosa Melero,NayaraPanizo,MarianGoicoechea,
PatrocinioRodr´ ıguez-Ben´ ıtez, SoledadGarc´ ıaVinuesa,EduardoVerde,
AlbertoTejedor,andJos´ eL u˜ no
Nephrology Department, Hospital General Universitario Gregorio Mara˜ n´ on, Street Dr. Esquerdo 46, 28007 Madrid, Spain
Correspondence should be addressed to David Arroyo, dvdrry@gmail.com
Received 17 May 2011; Accepted 8 June 2011
Academic Editor: Alejandro Mart´ ın-Malo
Copyright © 2011 David Arroyo et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Objectives.Metforministhepreferredoralantidiabetic agentfortype2diabetes.Lactic acidosisisdescribedasararecomplication,
usuallyduringanacutekidneyinjury(AKI).MaterialandMethods.Weconductedaprospectiveobservationalstudyofmetformin-
associatedAKIcasesduringfouryears.29caseswereidentiﬁed.Previousrenalfunction,clinicaldata,andoutcomeswererecorded.
Results. An episode of acute gastroenteritis precipitated the event in 26 cases. Three developed a septic shock. Three patients died,
the only related factor being liver dysfunction. More severe metabolic acidosis hyperkalemia and anemia were associated with
higher probabilities of RRT requirement. We could not ﬁnd any relationship between previous renal dysfunction and the outcome
of the AKI. Conclusions. AKI associated to an episode of volume depletion due to gastrointestinal losses is a serious complication
in type 2 diabetic patients on metformin. Previous renal dysfunction (mild-to-moderate CKD) has no inﬂuence on the severity or
outcome.
1.Introduction
Metformin is the only biguanide extensively used these
days, and has become the ﬁrst-line oral drug in type 2
diabetes [1]. Metformin-associated lactic acidosis has not
been thoroughly characterized. Meta-analyses and large
studies have been unable to establish an epidemiological
association, probably due to its low incidence rate. However,
most cases have been reported associated with an episode of
acute kidney injury (AKI), predominantly in intensive care
units [2–4]. Usual treatment includes correction of acidosis
and hyperkalemia using bicarbonate solutions, as well as
renal replacement therapies (RRT) [5].
Some coexisting conditions have been classically deﬁned
as contraindications for the use of metformin [6]. The
reason for including chronic kidney disease (CKD) probably
arises from the fact that most cases of lactic acidosis were
described in association with an AKI episode derived from
hypovolemia secondary to gastrointestinal losses. Experi-
mental studies and several series of cases show that adverse
outcomes seem more related to hepatic dysfunction than
to renal impairment [2, 3, 7]. The pharmacological eﬀect
of metformin, as well as the onset of lactic acidosis, could
be mediated in part through a self-limiting inhibition of
the respiratory chain that restrains hepatic gluconeogenesis
while increasing glucose utilization in peripheral tissues [8,
9].
This study describes the features of the AKI related to
metformin use to determine the prognostic inﬂuence of
previous CKD, in an attempt to ﬁnd if there is real evidence
to further consider renal impairment as a contraindication
for metformin prescription.
2.MaterialandMethods
2.1. Study Design. The study was developed at the Hos-
pital General Universitario Gregorio Mara˜ n´ on, in Madrid,
between 2006 and 2010. We recorded all patients with AKI
meeting RIFLE criteria for renal injury or failure. Patients
were included whenever they followed daily treatment with
metformin and had biochemical data of metabolic acidosis.
Clinicaldatawerecollected.Renalfunctionwasevaluated
(before—at least three months earlier and while in a healthy
state—, baseline and during followup). Serum creatinine2 International Journal of Nephrology
and estimated glomerular ﬁltration rate (eGFR) as calculated
with the MDRD-4-IMDS equation were recorded. Patients
were stratiﬁed according to the NKF-KDOQI criteria for
CKD stages according to their previous serum creatinine:
normal eGFR (over 60mL/min/1.73m2) and CKD (below
60), and those with CKD in stages 3a (eGFR between 45 and
59mL/min) and 3b (between 30 and 44).
2.2. Objectives. Our primary goal was to evaluate RRT
requirements in a crude, unadjusted analysis, stratiﬁed by
previous renal function. Secondary endpoints included renal
function at hospital discharge and three months later, and
all-cause mortality.
2.3. Statistical Analysis. All statistical analyses were per-
formed with SPSS, version 15.0.1 (SPSS Inc, Chicago, IL).
Categorical data were compared using the Chi-square test,
and continuous variables by means of a Student’s t-test.
Association between basalcharacteristicsand potential prog-
nostic factors was assessed in univariate analyses. Statistical
signiﬁcance was deﬁned as a two-tailed P < 0.05.
3. Results
Twenty-nine patients were included, thirteen men and
sixteen women, with a mean age of 72.00 ± 8.78 years
(Table 1). The daily metformin dose was 1700 to 2550mg.
Baseline mean serum creatinine concentration was 105.20 ±
29.17µmol/L: seventeen patients (59%) had baseline stage
3 CKD (28% stage 3a and 31% stage 3b). Twenty-six
patients were admitted into the emergency unit with volume
depletion in the context of gastrointestinal losses, most of
them 24 to 72 hours after the beginning of the symptoms.
Theremainingthreehadasepticshock.Themeanlaboratory
values at the time of admission are summarized in Table 1.
Ninepatients(30%)weretreatedwithintravenousﬂuids,
including administration of bicarbonate, and medical man-
agement of hyperkalemia. The other twenty also required
RRT: eleven (55%) with continuous techniques and nine
with intermittent hemodialysis. Fifteen patients (51.7%)
required ICU admission.
PatientswithlowerplasmapH,higherlevelofpotassium,
lower serum proteins, and lower hemoglobin concentration
had a higher probability of requiring RRT (Table 2). We
detected no cases of lactic acidosis related to long-term
metformin use without a concomitant AKI. Previous renal
dysfunction had no inﬂuence on the outcome: a worse
chronic kidney disease stage did not imply a higher risk
of needing dialysis. In fact, 91.7% of the patients with a
previous eGFR over 60mL/min/1.73m2 needed RRT, yet
only 47.1% of the patients with CKD did (P = 0.013). This
signiﬁcant diﬀerence could also be seen in the subgroups
analysis (Figure 1).
Three patients died: one, secondarily to refractory septic
shock, and two cirrhotic patients developed concomitant
liver failure. The average in-hospital length of stay was 15.66
± 11.02 days. Renal function prognosis was good: the mean
creatinine at hospital discharge was 138.79 ± 42.43µmol/L.
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Figure 1:Inﬂuenceofpreviousrenalfunctiononrenalreplacement
therapy requirement during the acute kidney injury episode.
Number and percentage of patients that required renal replacement
therapies in relation with previous renal function. ∗Previous
renal function expressed as estimated glomerular ﬁltration rate
in mL/min/1.73m2 calculated according to the MDRD-4-IMDS
formula.
Three months after discharge, the mean creatinine was
106.96 ± 38.01µmol/L.
4. Discussion
In our study, mild-to-moderate CKD is not associated with
the risk of developing the AKI episode. CKD is neither
associated with a more severe acidosis nor does it imply a
highermorbimortality.Incontrast,inourstudy,thegroupof
patients withmoderateCKDhaslowerRRTrequirements,as
a proof of a less severe episode. This fact cannot be explained
by means of a more profound hypotension or a higher rate
of SRAA blockers use. Because of that, we consider it safe
that this group of patients could continue with metformin
treatment.
Volume depletion and hypoperfusion appear more
important in the severity of metformin-related metabolic
acidosis when associated with an AKI. Thus, patients
undergoing any risk situation for volume depletion would
beneﬁt from a temporary interruption in their metformin
treatment. This is a regular practice for radiological studies
with iodated contrasts, as part of nephrotoxicity prophylaxis.
It could also become a good practice for primary care
physicians to advice patients on metformin to temporarily
interrupt this treatment whenever they develop any other
potential danger, particularly diarrhea or vomiting. We
believe that this simple practice would lower the rate of this
complication of metformin.
Previous renal dysfunction has been described as a
potential risk factor of metformin-associated lactic acidosis
and most guidelines support CKD as a contraindication.
While CKD stages 4-5 (eGFR below 30) are accepted as anInternational Journal of Nephrology 3
Table 1: Clinical and analytical characteristics of the patients.
Patients classiﬁed according to renal function
All patients
n = 29
eGFR >
60mL/min∗
n = 12
eGFR <
60mL/min∗
n = 17
P†
Age
Gender (M/F) (%)
72 ± 8.78
44.8/55.2
70.33 ± 5.74
50/50
73.18 ± 10.42
41.2/58.8
0.40
0.64
Coexisting conditions (%):
(i) Hypertension 100 100 100 —
(ii) Chronic heart disease 38 25 53 0.13
(iii) Cerebrovascular disease 31 25 35 0.56
(iv) Cancer 24 33 18 0.33
(v) Liver disease 10 8 12 0.77
(vi) Peripheral vasculopathy 10 0 18 0.12
(vii) Chronic respiratory disease 3 8 0 0.23
Other treatments (%):
Antihypertensive drugs: ‡
(i) RAAS blockers 86 91.7 82.4 0.47
(a) of which ACE inhibitors 59
(b) of which ARB 24
(c) of which dual block 3
(ii) Diuretics 55 50 58.8 0.64
Other antidiabetic agents:
(i) Other oral antidiabetic drugs 41 33.3 47.1 0.46
(ii) Insulin 21 33.3 17.6 0.33
Laboratory values at diagnosis:
(i) Creatinine (µmol/L) 599.35 ± 299.68 675.38 ± 302.33 544.55 ± 295.26 0.25
(ii) eGFR (mL/min/1.73m2) 10.47 ± 7.94 8.73 ± 6.98 11.69 ± 8.55 0.33
(iii) Urea (mmol/L) 58.01 ± 20.75 58.52 ± 24.73 57.65 ± 18.23 0.91
(iv) pH 7.12 ± 0.19 7.12 ± 0.18 7.12 ± 0.20 0.96
(v) Lactate (mmol/L) 9.05 ± 4.99 8.92 ± 5.02 9.07 ± 5.16 0.94
(vi) Bicarbonate (mmol/L) 11.14 ± 7.23 10.84 ± 7.51 11.35 ± 7.25 0.86
(vii) Anion gap 29.03 ± 10.23 28.58 ± 12.51 28.94 ± 9.62 0.93
(viii) Sodium (mmol/L) 134.17 ± 7.09 135.42 ± 5.25 133.29 ± 8.20 0.44
(ix) Chloride (mmol/L) 94.24 ± 8.64 96 ± 7.82 93 ± 9.20 0.37
(x) Potassium (mmol/L) 5.65 ± 1.36 6.01 ± 1.09 5.40 ± 1.50 0.24
(xi) Phosphate (mmol/L) 2.48 ± 1.40 2.63 ± 1.89 2.37 ± 0.92 0.63
(xii) Hemoglobin (g/L) 117.7 ± 22.4 111.4 ± 17.1 122.1 ± 25.0 0.21
(xiii) Total serum proteins (g/L) 66.9 ± 12.4 68.3 ± 10.9 66.0 ± 13.5 0.64
(xiv) Albumin (g/L) 32.8 ± 5.1 32.9 ± 5.3 32.8 ± 5.2 0.96
Blood pressure at diagnosis (mm Hg):
(i) Systolic 119.31 ± 37.31 121.33 ± 42.84 117.88 ± 34.20 0.81
(ii) Diastolic 63.00 ± 19.50 62.09 ± 21.17 63.59 ± 18.98 0.85
(iii) Mean 81.41 ± 24.41 80.97 ± 28.44 81.69 ± 22.36 0.94
Endpoints:
(i) RRT requirement (%) 30 91.7 47.1 0.013
(ii) Creatinine at discharge (µmol/L) 138.79 ± 42.43 123.76 ± 28.29 150.28 ± 48.62 0.09
(iii) eGFR at discharge
(mL/min/1.73m2)∗ 42.72 ± 12.60 46.50 ± 13.03 39.95 ± 11.95 0.20
(iv) Creatinine 3 months after
discharge (µmol/L) 106.96 ± 38.01 99.01 ± 32.71 111.38 ± 40.66 0.474 International Journal of Nephrology
Table 1: Continued.
Patients classiﬁed according to renal function
All patients
n = 29
eGFR >
60mL/min∗
n = 12
eGFR <
60mL/min∗
n = 17
P†
(v) eGFR 3 months after discharge
(mL/min/1.732)∗ 63.82 ± 28.60 65.59 ± 22.43 62.73 ± 32.65 0.83
Mean ± standard deviation for quantitative variables; percentages for qualitative variables. ∗Estimated glomerular ﬁltration rate (eGFR) calculated according
to the MDRD-4-IMDS equation. †Signiﬁcant P values between groups highlighted in bold. ‡RAAS: renin-angiotensin-aldosterone system; ACE: angiotensin-
converting enzyme; ARB: aldosterone-receptor blockers.
Table 2: Prognostic factors for renal replacement therapy requirement.
RRT required RRT not
required P∗
Hemoglobin (g/L) 109.9 ± 16.8 134.7 ± 24.6 0.002
Potassium (mmol/L) 6.03 ± 1.11 4.81 ± 1.55 0.015
pH 7.06 ± 0.19 7.24 ± 0.09 0.023
Serum proteins (g/L) 63.3 ± 12.2 73.2 ± 10.5 0.041
Creatinine (µmol/L) 666.54 ± 309.40 449.07 ± 221.88 0.07
Bicarbonate (mmol/L) 9.51 ± 6.98 14.56 ± 6.35 0.08
Lactate (mmol/L) 9.54 ± 5.29 7.97 ± 4.32 0.44
Anion gap 29.75 ± 11.21 27.44 ± 7.99 0.59
Systolic blood pressure
(mmHg) 121.26 ± 43.30 115.60 ± 23.65 0.71
Diastolic blood pressure
(mmHg) 63.37 ± 20.32 62.22 ± 18.77 0.89
Mean blood pressure
(mmHg) 82.67 ± 27.35 78.74 ± 17.82 0.70
∗Signiﬁcant P values between groups highlighted in bold.
absolute contraindication, the information about moderate
CKD(eGFRbetween30and59)ismorecontroversial[10].It
is established as an absolute contraindication in the technical
information of the drug, but other guidelines of scientiﬁc
societies, such as the American Diabetes Association, permit
its use in patients with an eGFR > 30mL/min [1].
Recent studies point out liver disease as more important
risk and prognostic factors. Peters et al. [4] and Seidowsky
et al. [3] ﬁnd prothrombin time and prothrombin activity
respectively as the only analytical factors related to a higher
mortality. Furthermore, experimental studies highlight the
importance of the biochemical pathways aﬀected by this
drug, mainly glycolysis activation and inhibition of gluco-
neogenesis and mitochondrial respiratory chain complex 1,
both in liver cells [7–9]. The fact that two of our three deaths
were due to hepatic failure supports this idea.
4.1. Study Limitations. In spite of being one of the largest
series describing metformin-related AKI, our sample is
still comprised of a low number of patients. A larger
series could give more data on mortality predictive factors.
Also, a controlled study comparing the outcomes of
medical treatment versus RRT would shed light on the best
therapeutic approach.
5. Conclusion
In our study, stage 3 chronic kidney disease is not associated
with a higher risk for dialysis-dependent acute kidney
injury in patients who develop lactic acidosis while taking
metformin, and it seems not to inﬂuence prognosis. Thus,
metformin appears to be safe in this group of patients.
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